Oruka Therapeutics (ORKA) names chief commercial officer as insider

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) filed an initial statement of beneficial ownership (Form 3) for Larry Todd Edwards, who serves as Chief Commercial Officer. The filing lists him as an officer of the company and does not report any specific equity transactions or detailed holdings in this data.

Key Terms

initial statement of beneficial ownership, reporting person, derivativeSummary

3 terms

initial statement of beneficial ownership regulatory

"filed an initial statement of beneficial ownership (Form 3)"

An initial statement of beneficial ownership is the first regulatory filing an insider or large investor submits to disclose the amount of a company's stock they control or benefit from. It matters to investors because it reveals who has significant influence over a company—like showing who’s holding the cards—and helps track potential conflicts of interest, insider motives, and future buying or selling that can move the stock price.

reporting person regulatory

"The reporting person is Larry Todd Edwards"

derivativeSummary financial

"The derivativeSummary is empty and the derivative transaction"

FAQ

Who is the reporting person in Oruka Therapeutics (ORKA) Form 3?

The reporting person is Larry Todd Edwards, who is identified as an officer of Oruka Therapeutics, Inc. with the title Chief Commercial Officer. The Form 3 records his status as an insider for Section 16 reporting purposes.

What is the purpose of this Form 3 filed for ORKA?

This Form 3 serves as an initial statement of beneficial ownership for officer Larry Todd Edwards at Oruka Therapeutics, Inc. It establishes his insider status under SEC rules but does not list any specific transactions in this data.

Does the ORKA Form 3 show any insider stock purchases or sales?

No. The structured data for this Form 3 shows no reported buy or sell transactions, and the transaction counts for purchases, sales, gifts, and exercises are all zero.

What insider role does Larry Todd Edwards have at Oruka Therapeutics (ORKA)?

Larry Todd Edwards is reported as an officer of Oruka Therapeutics, Inc., with the title Chief Commercial Officer. He is not identified as a director or ten percent owner in this Form 3 data.

Does this ORKA Form 3 indicate any derivative securities for the insider?

No. The derivativeSummary is empty and the derivative transaction count is zero, indicating that no derivative securities or related transactions are reported in this Form 3 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/25/2026 - 04:11 PM Accepted by SEC EDGAR 08/25/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Edwards Larry Todd

(Last) (First) (Middle)

ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/24/2026

3. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Paul Quinlan, as attorney-in-fact for Larry Todd Edwards	08/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)